Clinical genomics operators are shifting from volume-led cash burn to operating leverage as standard-of-care guidelines institutionalize liquid biopsy and minimal residual disease tracking.
18 tickers·$103.78B market cap
10D-9.15%#1,365of 1,461 themes/1,461#3of 5 in Genomics/5 Genomics